Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program

Ceftaroline: Potential role and implications in an era of escalating antimicrobial resistance

(2011) E. B. Chahine   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Carbapenems: Past, Present, and Future

(2011) Krisztina M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftaroline fosamil: a new broad-spectrum cephalosporin

(2011) J. B. Laudano   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

(2011) Donald E. Low et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

(2011) T. M. File et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Affinity of Ceftaroline and Other  -Lactams for Penicillin-Binding Proteins from Staphylococcus aureus and Streptococcus pneumoniae

(2010) K. Kosowska-Shick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful Treatment for Carriage of Methicillin-Resistant Staphylococcus aureus and Importance of Follow-Up

(2010) F. P. N. Mollema et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia

(2010) Ronald N. Jones et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination

(2010) F. Perez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

(2010) M. H. Wilcox et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

(2010) G. R. Corey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection

(2010) Elizabeth B. Hirsch et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity

(2010) D. Biek et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Binding of Faropenem and Other  -Lactam Agents to Penicillin-Binding Proteins of Pneumococci with Various  -Lactam Susceptibilities

(2009) K. Kosowska-Shick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prospective Comparison of the Clinical Impacts of Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Susceptible MRSA

(2009) K. C. Horne et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007)

(2009) Douglas J. Biedenbach et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Detection of Staphylococcal Cassette Chromosome mec-Associated DNA Segments in Multiresistant Methicillin-Susceptible Staphylococcus aureus (MSSA) and Identification of Staphylococcus epidermidis ccrAB4 in both Methicillin-Resistant S. aureus and MSSA

(2008) A. C. Shore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Resistance:Acinetobacter baumannii:Epidemiology, Antimicrobial Resistance, and Treatment Options

(2008) Lisa L. Maragakis et al.   CLINICAL INFECTIOUS DISEASES

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES